TITLE

RAD001 maintained extension of PFS in renal cell carcinoma

PUB. DATE
April 2009
SOURCE
Hem/Onc Today;4/10/2009, Vol. 10 Issue 7, p15
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article presents findings of a phase-3 trial of the efficacy of oral mammalian target of rapamycin (mTOR) inhibitor RAD001 in patients with metastatic renal cell carcinoma.
ACCESSION #
37292856

 

Related Articles

  • Living-donor transplantation after excision of unrecognized renal cancer diagnosed after transplant. Melgosa Hijosa, Marta; Alonso Melgar, Angel; Martínez Urrutia, Mª; García Meseguer, Carmen; Jaureguizar Monereo, Enrique; Navarro Torres, Mercedes // Pediatric Nephrology;Dec2012, Vol. 27 Issue 12, p2319 

    Background: Published data on kidneys transplanted after resecting small renal cancers during the transplantation surgery are very rare and, to the best of our knowledge, no pediatric cases have been reported in the literature. Case-Diagnosis/Treatment: Our patient was diagnosed with a bilateral...

  • The Torisel trials in advanced renal cell carcinoma. Erotocritou, Paul P.; Patel, Sima S. // Advances in Oncology;2010, Vol. 5 Issue 2, p5 

    The article discusses the clinical trials of temsirolimus (Torisel), a synthetic derivative of oral rapamycin, in advanced renal cell carcinoma (RCC) in Great Britain. It reveals the effectiveness of Torisel in treating patients with RCC with poor diagnostic features. It also discusses the...

  • Temsirolimus, interferon alfa or both in advanced renal-cell carcinoma: One plus one does not always equal two. Grover, S.; Singh, J. C.; Kekre, N. S. // Indian Journal of Urology;Jul-Sep2007, Vol. 23 Issue 3, p332 

    This Phase 3 multicenter randomized trial[1] compared interferon alone, temsirolimus alone or the combination of both for the treatment of newly diagnosed metastatic renalcell carcinoma. From July 2003 to April 2005, a total of 626 patients were randomly assigned to one of the three study...

  • Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma. KAZUYUKI NUMAKURA; NORIHIKO TSUCHIYA; SUSUMU AKIHAMA; TAKAMITSU INOUE; SHINTARO NARITA; MINGGUO HUANG; SHIGERU SATOH; TOMONORI HABUCHI // Oncology Letters;2014, Vol. 8 Issue 1, p464 

    This study presents a case of metastatic sarcomatoid renal cell carcinoma (RCC) treated with systemic chemotherapy followed by mammalian target of rapamycin inhibitor maintenance therapy. A 63-year-old male presented with lumbago, and lumbar vertebral tumors were detected by magnetic resonance...

  • Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma. Cho, Daniel; Signoretti, Sabina; Dabora, Sandra; Regan, Meredith; Seeley, Apryle; Mariotti, Mauro; Youmans, Amanda; Polivy, Adam; Mandato, Lucy; McDermott, David; Stanbridge, Eric; Atkins, Michael // Clinical Cancer Update;Dec2007, Vol. 1 Issue 1, p85 

    Purpose: Similar to other molecularly targeted agents, temsirolimus, an inhibitor of mammalian target of rapamycin, has shown promising activity in advanced renal cell carcinoma. However, only a subset of patients appears to derive significant tumor responses. In an effort to identify potential...

  • Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases. Areses, Maria; Herranz, Urbano; Ferrán, Beatriz; Mateos, Luis; González, Jorge; López, Rafael // Medical Oncology;Jun2012, Vol. 29 Issue 2, p795 

    Renal cell carcinoma (RCC) with sarcomatoid features has an aggressive course. There is no standard treatment for this histological subtype. Some authors have previously reported the use of chemotherapy, but the activity of new agents against renal carcinoma with sarcomatoid differentiation has...

  • Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Porta, C.; Tortora, G.; Linassier, C.; Papazisis, K.; Awada, A.; Berthold, D.; Maroto, J.; Powles, T.; Santis, M. // Medical Oncology;Sep2012, Vol. 29 Issue 3, p1896 

    With six targeted agents approved (sorafenib, sunitinib, temsirolimus, bevacizumab [+interferon], everolimus and pazopanib), many patients with metastatic renal cell carcinoma (mRCC) will receive multiple therapies. However, the optimum sequencing approach has not been defined. A group of...

  • MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. Cui, Li; Zhou, Hua; Zhao, Hu; Zhou, Yaojun; Xu, Renfang; Xu, Xianlin; Zheng, Lu; Xue, Zhong; Xia, Wei; Zhang, Bo; Ding, Tao; Cao, Yunjie; Tian, Zinong; Shi, Qianqian; He, Xiaozhou // BMC Cancer;2012, Vol. 12 Issue 1, p546 

    Background: A growing body of evidence suggests that microRNAs (miRNAs) play an important role in cancer diagnosis and therapy. MicroRNA-99a (miR-99a), a potential tumor suppressor, is downregulated in several human malignancies. The expression and function of miR-99a, however, have not been...

  • Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer. Di Lorenzo, Giuseppe; Scagliarini, Sarah; Di Napoli, Marilena; Scognamiglio, Florinda; Rizzo, Mimma; Carteni, Giacomo // Oncology;2009 Supplement 1, Vol. 77, p122 

    The treatment of metastatic renal cell carcinoma (MRCC) has evolved from being predominantly cytokine-based to being grounded in the use of drugs targeting vascular endothelial growth factor, platelet-derived growth factor and mammalian target of rapamycin (mTOR) pathways. New agents including...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics